Genentech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genentech sits in the top decile of US sponsors by registered trial count (#110 of 15,742 sponsors by registered trial count).
Genentech: 332 sponsored US clinical trials, 23 recruiting.
Genentech sponsors 332 registered US clinical trials on ClinicalTrials.gov, 23 of them currently recruiting, and 259 completed. 45 of these trials are in Phase 3-4 (later-stage) and 267 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 10 trials.
Top-decile sponsor footprint
Genentech ranks in the top decile of sponsors by registered trial count (#110 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
259 of 292 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
332 total, page 7 of 7
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
NCT00406419
An Observational Study of the Use and Safety of Xolair® During Pregnancy
NCT00373061
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
NCT00287716
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
NCT00671372
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00381810
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
NCT00287729
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
NCT00282308
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
NCT00257608
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
NCT00130728
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
NCT00096928
An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)
NCT00097240
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00096993
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
NCT00097188
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00090623
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00091663
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
NCT00095225
A Safety and Efficacy Study of Xolair in Peanut Allergy
NCT00086606
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
NCT00081614
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
NCT00097578
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
NCT00080223
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
NCT00063154
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
NCT00061594
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
NCT00097513
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
NCT00047762
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
NCT00027027
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
NCT00047736
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
NCT00005635
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
NCT00002005
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
NCT00002004
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
NCT00002250
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
NCT00001992
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 162 |
| Phase 2 | 105 |
| Phase 3 | 30 |
| Phase 4 | 15 |
Therapeutic Areas
What is open in the Genentech pipeline
23 recruiting of 332 indexed (7% open); 259 completed (78%).
Phase mix: 45 late (III/IV) vs 267 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genentech: open-pipeline peers nationwide
Peers matched on 332 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Genentech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 332 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institute on Drug Abuse (NIDA) · 335 trials · 4% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 7% open enrollment (± trial volume)
- H. Lundbeck A/S · 7% recruiting · 72 trials
- BioCryst Pharmaceuticals · 7% recruiting · 29 trials
- Wake Forest University · 7% recruiting · 100 trials
- Agios Pharmaceuticals · 7% recruiting · 44 trials
Related
What to do with this Genentech page
332 registered trials is a research-attention snapshot, not an endorsement of Genentech or any single study.
- 23 of Genentech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Genentech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Genentech pipeline card: 332 registered trials from official public datasets.Report a data error.